555 results about "Glycation" patented technology

A method of determining glycated hemoglobin is provided, by which a ratio of the glycated hemoglobin in a sample can be determined accurately and easily. The ratio of glycated hemoglobin can be determined by degrading a glycated hemoglobin in a whole blood sample selectively with a protease to give a glycated hemoglobin degradation product`; causing a redox reaction between a glycation site of the glycated hemoglobin degradation product and a fructosyl amino acid oxidoreductase; and determining this redox reaction. Further, as shown in FIG. 1, in a whole blood sample, there is a correlation between the ratio of the glycated hemoglobin determined by this method and an HbA1c concentration. Thus, without determining the glycated alpha-amino group as a characteristic structure of HbA1c, an amount of HbA1c can be determined accurately and easily from the determined ratio of the glycated hemoglobin.

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual is disclosed. A portion of the skin of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can illuminate the skin and detect responsive light over a time that spans a plurality of cardiac cycles of the individual, which can, as an example, help mitigate the effects of time-varying signals such as those due to hemoglobin. The invention can also determine the amount of light to be directed to the skin, for example by controlling the time that a light source is energized. The amount of illumination light can be determined from a skin reflectance characteristic such as pigmentation or melanin in the skin. Controlling the amount of light directed to the tissue can reduce the dynamic range required of a corresponding optical system, for example by allowing a single system to accurately measure individuals with very light skin and individuals with very dark skin.

Embodiments of the present invention provide an apparatus suitable for determining properties of in vivo tissue from spectral information collected from the tissue. An illumination system provides light at a plurality of broadband ranges, which are communicated to an optical probe. The optical probe receives light from the illumination system and transmits it to in vivo tissue and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe communicates the light to a spectrograph which produces a signal representative of the spectral properties of the light. An analysis system determines a property of the in vivo tissue from the spectral properties. A calibration device mounts such that it is periodically in optical communication with the optical probe.

The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase, and peroxidase. The invention provides kits for performing the methods of the invention.

The invention discloses Pichia pastoris strain with alpha-1, 6-mannosyl transferase absent and the establishing method, which belongs to the biological engineering field. The collection number of the Pichia pastoris strain with alpha-1, 6-mannosyl transferase absent is CGMCC No.1853. The invention has the advantages that the Pichia pastoris strain with alpha-1, 6-mannosyl transferase absent built by the invention can prevent the generation of excessive manna saccharify, when expressing extrinsic glucoprotein, reduce the immunogenicity of the pressed protein, and therefore, the invention has important application value in the biomedical field, and other fields; simultaneously, the strain can also be applied to the further gene knockout or the metabolic engineering reconstruction. The invention also builds a method for knocking out the alpha-1, 6-mannosyl transferase gene through secondary homologous recombination, mutant strain can be relatively easily obtained through the method, therefore the sieving workload is greatly reduced, and the success ratio is improved.

The invention discloses low molecular weight carboxyl-reduced derivatives of fucosylated glycosaminoglycans (LCRG). The extent of carboxyl reduction is not less than 20%. Weight-average molecular weight of the LCRG is about 3000-20000Da, and monosaccharides comprise acetyl galactosamine (GalNAc), glucose (Glc) or glucuronic acid (GlcUA) and fucose (Fuc) or sulfates of fucose (shown as -OSO3-). The mole ratio of GalNAc, Glc (containing GlcUA), Fuc and -OSO3- is about 1: (1+-0.3): (1+-0.3): (3.0+-1.0). The LCRG is a potent human immunodeficiency virus (HIV) Type 1 entry inhibitor which acts on conserved regions and has the advantages of high activity against HIV Type 1, high therapeutic index and no-drug-resistance, and the LCRG can be used for preventing or curing HIV. The invention further provides a preparation method of the LCRG. The carboxyl-reduced derivatives of fucosylated glycosaminoglycans and medicinal compositions of the carboxyl-reduced derivatives can be prepared into injection agents, lyophilized powder or suppository and the like.

The invention provides a derivate of low molecular weight fucosylated glycosaminoglycan (dLFG) and a medical composition containing the dLFG or pharmaceutically acceptable salt and application of the dLFG and the medical composition for preparing medicines for treating thrombotic diseases.

To provide a cholesterolemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering serum cholesterol. And to provide a triglyceridemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering triglycerides.

The invention relates to an enzymatic measuring method of glycosylated serum protein and a relative liquid stabilizer, with wide application in medical and biochemical technical field. The invention is characterized in that glycosylated serum protein is digested by bromelain to generate fructose amino acid, fructose amino acid oxidase is reacted with the fructose amino acid to generate H2O2 to be reacted with chromogen DA-64 in the presence of peroxidase to convert DA-64 into one green product, the product content is in direct proportion with glycosylated serum protein content of sample, and an automatic biochemical analyzer uses two-point end point method to measure the content of glycosylated serum protein in the sample. The inventive liquid measuring agent has high stability, easy application, strong interference resistance and non pollution on the pipeline of automatic biochemical analyzer, which is suitable for automatically measuring glycosylated serum protein in batch.

The invention discloses a trichoderma viride W2 capable of producing a thermophilic ethanol-resistant beta-glucosidase and an application thereof. The trichoderma viride W2 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on August 23, 2010, and the preservation number of the trichoderma viride W2 is CGMCC No.4098. The trichoderma viride W2 can produce a new beta-glucosidase, the enzymatic activity of the new beta-glucosidase reaches 346.7U/mL, the optimal reaction pH value is 4.8, the optimal reaction temperature is 70 DEG C, and the new beta-glucosidase is suitable for pyrohydrolysis and has an obvious glucose feedback inhibition effect. The ethanol the concentration of which is 10% has a maximal effect on promoting the enzymatic activity and improves the enzymatic activity of the beta-glucosidase by 1.6 times, and the resistant ability of the ethanol reaches 30%, so that the cellobiose inhibition can be effectively eliminated, the yield of the ethanol is improved by nearly 3 times, and the terminal product inhibition is effectively eliminated. Thus, the beta-glucosidase can be used for simultaneous saccharification and fermentation of lignocellulose raw materials, has a rare promoting effect in China, effectively increases the yield of the cellulosic ethanol, lowers the production cost, and accelerates the industrialized progress of the cellulosic ethanol.

The invention relates to an enzymatic test kit for glycosylated hemoglobin, which is composed of hemolysis buffer solution, reagent R1a, reagent R1b and reagent 2; wherein, the hemolysis buffer solution is 10 to 1000mmol/ L N- cycloethyl-2-aminoethanesulfonic acid, 10 to 1000mmol/L MOPS and 1 to 100g/L polyethylene glycol oxide dodecyl ether; the reagent R1a is 100 to 10000 kU/L metalloproteinase, 0.1 to 10mmol/L 2-(iodophenyl)-3-(2, 4- dinitrobenzene)-5-(2, 4-disulfophenyl)-2H tetrazole sodium salt; the reagent R1b is 0.1 to 10mmol/L MES and 0.5 to 50mmol/L CaCl2; the reagent 2 is 1 to 100kU/L fructose valine oxidase with high activity, 30 to 600kU/L POD, 0.01 to 0.5mmol/L DA-64 and 10 to 1000mmol/L Tris-HCl. The test kit coincides with the characteristics of rapidness, large batch size and economy which are required by the glycosylated hemoglobin clinical tests.

A method of improving the flow properties or cold solubility of a milk powder and use of the modified powder in beverage distribution machine for delivering, in particular, cold beverages. The method includes controlling glycation of proteins in the range of 10 to 35% blocked lysine and lactose crystallization between 5 and 50%. The resulting powder also represents an embodiment of the invention.

The invention relates to a method for the production of at least one microbial metabolic product having at least 3 C atoms or at least 2 C atoms and at least one N atom by means of sugar-based microbial fermentation. The inventive method involves the following steps: a) producing a sugar-containing liquid medium having a monosaccharide content of more than 20 weight percent from a starch source, wherein the sugar-containing liquid medium also comprises nonstarch-containing solid components of the starch source; b) fermenting the sugar-containing liquid medium for the production of the metabolic product(s) and c) separating or isolating at least one metabolic product from the fermentation broth, wherein the microorganism strain producing the desired metabolic product(s) is cultivated with the sugar-containing liquid medium, which is obtained by: a1) milling the starch source and a2) liquefying the ground material in an aqueous fluid in the presence of at least one starch liquefying enzyme and subsequently saccharifyng the resulting liquid using at least one saccharifying enzyme, wherein at least part of the ground material is liquefied into an aqueous liquid by continuous or discontinuous addition.